Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | ALK-TKIs: targeted therapies for ALK-positive NSCLC

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, discusses the changing treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Passaro reports that whereas chemotherapy was the major treatment option in the past, newly emerging targeted therapies prompted the introduction of ALK tyrosine kinase inhibitors (TKIs) as the first-line treatment for ALK-positive NSCLC.